Shirali Agarwal

Hematology Oncology
825 Eastlake Ave E
Seattle, WA 98109

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications

Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children's Oncology Group AALL1931 study.

Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children's Oncology Group AALL1931 study.

Journal: Blood advances
Published: April 08, 2024

A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome.

A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome.

Journal: Blood advances
Published: February 16, 2023

Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study.

Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study.

Journal: Blood
Published: June 22, 2022

A phase II, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.

A phase II, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Journal: Haematologica
Published: May 30, 2022

Pre-transplant myeloid and immune suppression, upfront plerixafor mobilization and post-transplant cyclophosphamide: novel strategy for haploidentical transplant in sickle cell disease.

Pre-transplant myeloid and immune suppression, upfront plerixafor mobilization and post-transplant cyclophosphamide: novel strategy for haploidentical transplant in sickle cell disease.

Journal: Bone marrow transplantation
Published: May 08, 2020

Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AML.

Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AML.

Journal: Cancer medicine
Published: April 03, 2020

Primary intracranial choriocarcinoma in a very youngest child.

Primary intracranial choriocarcinoma in a very youngest child.

Journal: Pediatric blood & cancer
Published: September 23, 2016
Showing 1-7 of 7

Last Updated: 09/26/2026